CIA

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout

By

The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

Novartis sued for alleged speaker-program abuse

By

The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

By

Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.

CIAs pressure pharma to rethink sales rep compensation

By

Novartis's recent off-label settlement with the Department of Justice -- to the tune of $422 million -- also included the signing of a Corporate Integrity Agreement (CIA) requiring the Swiss-based manufacturer to review incentive-based compensation for reps, and to examine "the extent to which compensation is based on product performance," according to the CIA.

Sales reps at J&J unit to get 'ride-alongs' as part of CIA

By

As part of an $81 million off-label settlement with the Department of Justice (DOJ), Ortho-McNeil Janssen Pharmaceuticals Inc. (OMJPI) sales reps will be buddied up with internal compliance monitors tasked with observing and reporting the rep's behavior out in the field.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters